The chimeric anti-CD-20 antibody, rituximab is among standard treatment regimes in treating B-cell Non-Hodgkin’s lymphoma. The possibility of conjugation and subsequent radiolabeling with beta (gamma) - emmiting radioisotopes can provide an added value to this therapeutical, thus increasing the possibility of targeted action to mature, malignant B-cells. Furthermore, designing a “ready to label”, freeze-dried immunoconjugate holds much advantages both in preserving the antibody stability and in the preparation and labeling with radioisotopes. Design of freeze-dried immunoconjugate kit was the main aim of this work, specifically in decision whether to add or not a cryoprotective and bulking agent, mannitol. For this purpose, rituximab, pre...
The purpose of this investigation was to introduce a technology for ready to use production of cold ...
Monoclonal antibody Trastuzumab is the first humanized approved antibody for tratment of HER-2 posit...
The beginning of the new century brought approval of two monoclonal antibodies for therapy of Non Ho...
Preparations containing antibodies are more easily formulated in solution, but their stability is of...
The purpose of this investigation was to introduce a technology for the production of ready-to-use c...
Monoclonal antibodies (mAbs) are currently assessed as a significant and growing class of drugs of b...
Monoclonal antibodies (mAbs) are currently assessed as a significant and growing class of drugs of b...
Two radiolabelled monoclonal antibodies are approved for the treatment of non-Hodgkin’s lymphoma, Yt...
Various radiolabeled monoclonal antibodies have been developed for the treatment and diagnosis of ma...
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to...
Background: Positron emission tomography (PET) has a growing use in medical decision making and mana...
The purpose of this investigation was to introduce a technology for ready to use production of cold ...
Radioimmunoconjugates are promising agents in diagnostic and treatment of different types of cancers...
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to...
Trastuzumab is a humanized anti-HER2 monoclonal antibody used for therapy of metastatic breast cance...
The purpose of this investigation was to introduce a technology for ready to use production of cold ...
Monoclonal antibody Trastuzumab is the first humanized approved antibody for tratment of HER-2 posit...
The beginning of the new century brought approval of two monoclonal antibodies for therapy of Non Ho...
Preparations containing antibodies are more easily formulated in solution, but their stability is of...
The purpose of this investigation was to introduce a technology for the production of ready-to-use c...
Monoclonal antibodies (mAbs) are currently assessed as a significant and growing class of drugs of b...
Monoclonal antibodies (mAbs) are currently assessed as a significant and growing class of drugs of b...
Two radiolabelled monoclonal antibodies are approved for the treatment of non-Hodgkin’s lymphoma, Yt...
Various radiolabeled monoclonal antibodies have been developed for the treatment and diagnosis of ma...
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to...
Background: Positron emission tomography (PET) has a growing use in medical decision making and mana...
The purpose of this investigation was to introduce a technology for ready to use production of cold ...
Radioimmunoconjugates are promising agents in diagnostic and treatment of different types of cancers...
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to...
Trastuzumab is a humanized anti-HER2 monoclonal antibody used for therapy of metastatic breast cance...
The purpose of this investigation was to introduce a technology for ready to use production of cold ...
Monoclonal antibody Trastuzumab is the first humanized approved antibody for tratment of HER-2 posit...
The beginning of the new century brought approval of two monoclonal antibodies for therapy of Non Ho...